Short Talks

The Alzheimer’s Drug Discovery Foundation had invited young investigators (including graduate students, post-doctoral fellows, and early-stage faculty) to submit their work related to drug development for neurodegeneration, for the Short Presentations.

Upon acceptance, presenters had recorded a video “walkthrough” of their presentation (no longer than 4 minutes), which will act as a guided presentation for attendees to review. To provide attendees the opportunity to ask questions about the short presentations, we will be hosting live Q&A sessions as outlined in our program.

Each such presentation (recording and abstract) will have its own chatroom where the presenter can interact with multiple attendees/visitors. Additionally, video chats will also be available from the chat modules.

These lectures are typically work-in-progress. We expect attendees to treat the short presentations exactly as they would in-person talks and not to cite them without permission of the presenter.

The following individuals will present:

Joel Annor-Gyamfi, PhD, University of North Carolina at Chapel Hill
Potential Small Molecule Inhibitors of the Moesin-CD44 Pathway Implicated in AD Pathology

Gizem Antika, MS, Canakkale Onsekiz Mart University
The Potential Inhibitory Effect of Strigolactones On Nlrp3 Activation in Microglia Cells

Nora Astrain-Redin, PhD (cand.), University of Navarra
Novel Selenocompounds Evocating Garlic-active Components as Acetylcholinesterase Inhibitors

Shreaya Chakroborty, PhD, National Institute on Aging
Alzheimer’s Disease Preclinical Efficacy Database (AlzPED): Optimizing the Predictive Power of Drug Efficacy Studies in Alzheimer’s Disease Animal Models

Despoina Charou, PhD (cand.), University of Crete
Characterization of New Microneurotrophin Mimetics in Countering Neurodegeneration

Feixiong Cheng, PhD, Cleveland Clinic
Multimodal Single-cell/nucleus RNA-sequencing Data Analysis Uncovers Molecular Networks between Disease-associated Microglia and Astrocytes with Implications for Drug Repurposing in Alzheimer’s Disease

Michael Chvanov, PhD, University of Liverpool
Lysosome-acidifying Small-molecule Drugs Against Neurodegenerative Diseases

Jagadeesh Dhamodharan, PhD (cand.), AIMST University
Therapeutic Potential of Gefitinib in B-amyloid Oligomer Induced Alzheimer’s Disease in Swiss Albino Mice

Louis Dwomoh, PhD, MS, University of Glasgow
Slowing Prion Disease Via M1 Muscarinic Receptors Is Associated with Reduced Neuroinflammation And Down-regulation of Neurodegenerative Disease Markers

Liberty Francois-Moutal, PhD, University of Arizona
Rtrd01, A Promising Compound in Neurodegeneration Therapeutics

Mandana Hunter, PhD, University of Pennsylvania
Microglial Transcriptome Analysis in the rNLS8 Mouse Model of TDP-43 Proteinopathy Reveals Discrete Expression Profiles Associated with Neurodegenerative Progression and Recovery

Jahirul Islam, PhD (cand.), Seoul National University
GPCR19 Regulates P2x7r-mediated Nlrp3 Inflammasomal Activation of Microglia in Mice with Alzheimer’s Diseases

Sarah Jolly, PhD, UCL
Notum, A Negative Regulator of Wnt Signalling, as a Therapeutic Target for Alzheimer’s Disease? From Target Validation to The Development of Small Molecule Inhibitors

Nicole Kasica, PhD (cand.), Wake Forest University
Memory Impairments and Synaptic Failure in Tg19959 And APP/PS1 AD Model Mice Are Alleviated by Eef2k Inhibitor A-484954

Yeojung Koh, MS, Case Western Reserve University
Protective Efficacy of Selective 15-hydroxy Prostaglandin Dehydrogenase Inhibition on Alzheimer’s Disease-like Pathology In 5xfad Mice

SangJoon Lee, PhD, St. Jude Children’s Research Hospital
The MicroRNA Mir485-3p Antisense Oligonucleotides Reduces Pathology of Alzheimer’s Disease

Khian Giap Lim, PhD (cand.), AIMST University
Ameliorative Potential of Beta-carotene in Streptozotocin-induced Diabetic Vascular Dementia in Rats

Juliana Mozer Sciani, PhD, Universidade Sao Francisco
Caissarine A and Analogues Design for BACE-1 Inhibition In Silico Sar Approach for a Drug Prototype

Arunachalam Muthuraman, PhD, AIMST University
Therapeutic Investigation of Cycloastragenol in the Intracerebroventricular Injection of Streptozotocin-induced Vascular Dementia in Rats

Ramesh Neelamegam, PhD, UT Health San Antonio
Development of Selective Positron Emitting Radioligands for 4-repeat Tau Imaging

Bindu Paul, PhD, Johns Hopkins University
Neuroprotective Roles of Hydrogen Sulfide Donors in Alzheimer’s Disease

Krzysztof Potempa, PhD, BRAINCURES
Biological Intelligence Approach to Precision Medicine

Frances Potjewyd, PhD, The University of North Carolina at Chapel Hill
Towards the Exploration of a Covalent Mechanism for An Allosteric SYK Inhibitor to Investigate the Role of SYK in AD Pathology

Massimiliano Runfola, PhD, University of Pisa
Identification of A Novel Pleiotropic Agent for the Treatment of Alzheimer’s Disease

Cristina Sanchez-Puelles, PhD, Tetraneuron
E2f4dn-based Gene Therapy Recovers Long-term Potentiation and Hippocampal-dependent Memory in Homozygous 5xfad Mice

Paul Seidler, PhD, University of Southern California
Reversing Pathological Folds: Discovery of Brain-penetrating Small Molecule Disaggregants Using an Alzheimer’s Brain-derived Tau Fibril Pharmacophore

Aswinprakash Subramanian, PhD (cand.), AIMST University
Astaxanthin Ameliorates the Diabetic Retinopathy Associated Visual Spatial Cognitive Dysfunction in Swiss Albino Mice

Ann Tiiman, PhD, Karolinska Institute
Nonimmune-based Detection of Amyloidogenic Nanoplaques In Blood Serum of Patients with Alzheimer’s Disease. Towards Early Diagnosis Using Methods with Single-molecule Sensitivity

Alexey Tomilov, PhD, UC Davis
Novel Shc Blockers for Alzheimer’s Disease

Ellen Vromen, MD, Amsterdam UMC
Apoe ε4 Dose-dependent Alterations in the Cerebrospinal Fluid Proteome of Prodromal Alzheimer’s Disease Individuals

Connie Wong, PhD (cand.), UT Southwestern Medical Center
Prevention of Alzheimer’s Disease Through Nhe6 Depletion

Angela Wu, PhD, University of Auckland
Nmda Receptor as A Potential Target for Immunomodulatory Therapy

Biyue Zhu, PhD, Massachusetts General Hospital
Reporting Amyloid Beta Levels via Bioluminescence Imaging with Amyloid Reservoirs

Share This